Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 404

1.

Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk.

Sun J, Wiklund F, Hsu FC, Bälter K, Zheng SL, Johansson JE, Chang B, Liu W, Li T, Turner AR, Li L, Li G, Adami HO, Isaacs WB, Xu J, Grönberg H.

Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):480-5.

2.

Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer.

Chen YC, Giovannucci E, Kraft P, Lazarus R, Hunter DJ.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1982-9.

3.

Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.

Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H.

J Natl Cancer Inst. 2005 Apr 6;97(7):525-32.

PMID:
15812078
4.

Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study.

Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Grönberg H.

Cancer Res. 2004 Apr 15;64(8):2918-22.

5.

Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer.

Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ.

Cancer Res. 2005 Dec 15;65(24):11771-8.

6.

Toll-like receptor heterodimer variants protect from childhood asthma.

Kormann MS, Depner M, Hartl D, Klopp N, Illig T, Adamski J, Vogelberg C, Weiland SK, von Mutius E, Kabesch M.

J Allergy Clin Immunol. 2008 Jul;122(1):86-92, 92.e1-8. doi: 10.1016/j.jaci.2008.04.039. Epub 2008 Jun 10.

PMID:
18547625
7.

Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.

Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JK.

Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1077-82.

8.

Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.

Zheng SL, Sun J, Cheng Y, Li G, Hsu FC, Zhu Y, Chang BL, Liu W, Kim JW, Turner AR, Gielzak M, Yan G, Isaacs SD, Wiley KE, Sauvageot J, Chen HS, Gurganus R, Mangold LA, Trock BJ, Gronberg H, Duggan D, Carpten JD, Partin AW, Walsh PC, Xu J, Isaacs WB.

J Natl Cancer Inst. 2007 Oct 17;99(20):1525-33. Epub 2007 Oct 9.

PMID:
17925536
9.

Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk.

Stevens VL, Hsing AW, Talbot JT, Zheng SL, Sun J, Chen J, Thun MJ, Xu J, Calle EE, Rodriguez C.

Int J Cancer. 2008 Dec 1;123(11):2644-50. doi: 10.1002/ijc.23826.

10.

Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) influences disease course in sarcoidosis.

Veltkamp M, van Moorsel CH, Rijkers GT, Ruven HJ, Grutters JC.

Tissue Antigens. 2012 Jan;79(1):25-32. doi: 10.1111/j.1399-0039.2011.01808.x.

PMID:
22150367
11.

Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.

Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H.

Cancer. 2003 Oct 1;98(7):1411-6.

12.

Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease.

Török HP, Glas J, Endres I, Tonenchi L, Teshome MY, Wetzke M, Klein W, Lohse P, Ochsenkühn T, Folwaczny M, Göke B, Folwaczny C, Müller-Myhsok B, Brand S.

Am J Gastroenterol. 2009 Jul;104(7):1723-33. doi: 10.1038/ajg.2009.184. Epub 2009 May 19.

PMID:
19455129
13.

Toll-like receptor 4 genetic variation and advanced prostate cancer risk.

Cheng I, Plummer SJ, Casey G, Witte JS.

Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):352-5.

14.

The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.

Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC, Dimitrov L, Chang B, Turner AR, Liu W, Adami HO, Suh E, Moore JH, Zheng SL, Isaacs WB, Trent JM, Grönberg H.

Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2563-8.

15.

Variants in the toll-like receptor signaling pathway and clinical outcomes of malaria.

Leoratti FM, Farias L, Alves FP, Suarez-Mútis MC, Coura JR, Kalil J, Camargo EP, Moraes SL, Ramasawmy R.

J Infect Dis. 2008 Sep 1;198(5):772-80. doi: 10.1086/590440.

PMID:
18662133
16.

Replication of prostate cancer risk loci in a Japanese case-control association study.

Yamada H, Penney KL, Takahashi H, Katoh T, Yamano Y, Yamakado M, Kimura T, Kuruma H, Kamata Y, Egawa S, Freedman ML.

J Natl Cancer Inst. 2009 Oct 7;101(19):1330-6. doi: 10.1093/jnci/djp287. Epub 2009 Sep 2.

PMID:
19726753
17.

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.

Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Bälter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs WB, Grönberg H, Xu J, Carpten JD.

J Natl Cancer Inst. 2007 Dec 19;99(24):1836-44. Epub 2007 Dec 11.

PMID:
18073375
18.

H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.

Lindmark F, Zheng SL, Wiklund F, Bensen J, Bälter KA, Chang B, Hedelin M, Clark J, Stattin P, Meyers DA, Adami HO, Isaacs W, Grönberg H, Xu J.

J Natl Cancer Inst. 2004 Aug 18;96(16):1248-54.

PMID:
15316060
19.

Genomic organization and transcript profiling of the bovine toll-like receptor gene cluster TLR6-TLR1-TLR10.

Opsal MA, Våge DI, Hayes B, Berget I, Lien S.

Gene. 2006 Dec 15;384:45-50. Epub 2006 Jul 29.

PMID:
16950576
20.

A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer.

Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J.

Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):759-64.

Supplemental Content

Support Center